DYSLIPIDAEMIA: REVEALing the effect of CETP inhibition in cardiovascular disease
Initial randomized trials of cholesteryl ester transfer protein (CETP) inhibitors were terminated early owing to adverse effects or futility. The REVEAL trial now shows the benefit of CETP inhibition in coronary heart disease. Despite raising HDL-cholesterol levels, the cardiovascular effect of CETP inhibitors is probably due to lowering of non-HDL-cholesterol levels.
Refers to The HPS3/TIMI55-REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N. Engl. J. Med.http://dx.doi.org/10.1056/NEJMoa1706444 (2017) | Ference, B. A. et al. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. JAMA 318, 947-956 (2017)